Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
June 11, 2021 03:00 ET
|
Novartis Pharma AG
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal...
Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
June 06, 2021 06:06 ET
|
Novartis Pharma AG
Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria1 – a key risk predictor in kidney disease...
Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
June 04, 2021 09:05 ET
|
Novartis Pharma AG
Tabrecta® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta...
Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
June 03, 2021 17:05 ET
|
Novartis Pharma AG
At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.60, 1.17) (p=0.30,...
Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
June 03, 2021 12:04 ET
|
Novartis Pharma AG
Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or...
Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
June 02, 2021 09:05 ET
|
Novartis Pharma AG
Primary analysis of ELARA trial demonstrated a 66% complete response rate and 86% overall response rate with one-time Kymriah infusion1Robust response observed in heavily pretreated patients in...
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
June 02, 2021 09:00 ET
|
Novartis Pharma AG
MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to the OS...
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
May 19, 2021 17:00 ET
|
Novartis Pharma AG
Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be...
Wichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt
April 27, 2021 01:00 ET
|
Novartis Pharma AG
Der Nettoumsatz sank im ersten Quartal um –2% (kWk¹, +1% USD) infolge der COVID-19-bedingten Vorratskäufe im Vorjahr (rund USD 0,4 Milliarden) Die Geschäftseinheit Pharmaceuticals blieb auf...
Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.
April 27, 2021 01:00 ET
|
Novartis Pharma AG
Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion) Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with...